---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034338"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:07.898835+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva: 108 patients complete 1-year brilaroxazine OLE; topline data expected Dec 2024

## Summary
- 108 patients completed 12-month treatment; over 250 completed 6 months in the OLE study.
- Long-term safety data from 100 patients with 12 months treatment now available for planned NDA submission.
- Brilaroxazine continues to be generally well tolerated in acute and stable schizophrenia patients.
- Topline 12-month long-term safety and efficacy data expected in December 2024.
- OLE study (RECOVER) completion anticipated in Q1 2025.

## SEC filing metadata
- accession: 0001437749-24-034338
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/0001437749-24-034338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/rvph20241111_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034338
- JSON: https://secwatch.observer/filing/0001437749-24-034338.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.